JBM (Healthcare) Signs 2025 Europharm License Agreement

Reuters
10/28
JBM (Healthcare) Signs 2025 Europharm License Agreement

JBM (Healthcare) Ltd. has announced that Europharm and Europharm HK have entered into the 2025 Europharm License Agreement on 28 October 2025. Under this agreement, Europharm will grant a license to Europharm HK to use a portion of the Factory from 1 December 2025 to 27 January 2028, for a monthly license fee of HK$247,000. The agreement follows the expiration of the previous license on 30 November 2025. The directors of both Jacobson and JBM, including their independent non-executive directors, consider the terms of the agreement to be fair, reasonable, on normal commercial terms, and in the best interests of the companies and their shareholders. Certain directors abstained from voting on the relevant board resolutions to avoid potential conflicts of interest.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JBM (Healthcare) Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10